Yuhan Corp
KRX:000100
Yuhan Corp
Other Equity
Yuhan Corp
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Yuhan Corp
KRX:000100
|
Other Equity
₩5B
|
CAGR 3-Years
-51%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Other Equity
₩15.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Other Equity
₩75.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
41%
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Other Equity
₩45.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
52%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Other Equity
₩59B
|
CAGR 3-Years
160%
|
CAGR 5-Years
79%
|
CAGR 10-Years
34%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Other Equity
₩13.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
28%
|
CAGR 10-Years
13%
|
|
Yuhan Corp
Glance View
In the bustling landscape of South Korea's pharmaceutical industry, Yuhan Corp. stands out as a venerable institution with a rich legacy and a forward-thinking approach. Founded in 1926, Yuhan has carved out a respected space in the market through its commitment to developing, manufacturing, and distributing a wide array of pharmaceutical and healthcare products. The company operates across multiple segments, focusing on prescription drugs, over-the-counter medications, and consumer health products that cater to various needs from chronic diseases to everyday health care. Yuhan’s product portfolio includes a combination of in-house innovations and collaborations with global leaders, which has allowed it to build a sustainable revenue stream and secure a substantial market share both domestically and internationally. At the core of Yuhan's business model is the strategic integration of research and development with commercial prowess. The company invests significantly in R&D to stay ahead of industry trends and meet evolving patient needs. This focus on innovation is complemented by strategic partnerships and licensing agreements with international pharmaceutical corporations, allowing Yuhan to introduce groundbreaking therapies to the Korean market. Additionally, Yuhan capitalizes on its robust distribution network, ensuring wide accessibility and penetration of its products. These efforts not only reinforce Yuhan’s position as a leader in the pharmaceutical sector but also fuel its steady financial growth, providing a reliable return on investment through a combination of direct sales and strategic partnerships.
See Also
What is Yuhan Corp's Other Equity?
Other Equity
5B
KRW
Based on the financial report for Dec 31, 2024, Yuhan Corp's Other Equity amounts to 5B KRW.
What is Yuhan Corp's Other Equity growth rate?
Other Equity CAGR 5Y
0%
Over the last year, the Other Equity growth was -89%. The average annual Other Equity growth rates for Yuhan Corp have been -51% over the past three years .
You don't have any saved screeners yet